drugset / Trial / NCT04390178
Convalescent Plasma as Treatment for Acute Coronavirus Disease (COVID-19)
Phase 1/2
Completed
10 enrolled
Joakim Dillner
Danderyd Hospital · collabKarolinska Institutet · collabKarolinska University Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
There is currently no effective treatment for COVID-19 except best supportive care. The aim is assess the safety, tolerability and efficacy of convalescent plasma for treatment of patients with varying degrees of COVID-19 illness.
Timeline
- Start
- 2020-04-10
- Primary completion
- 2020-06-30
- Completion
- 2020-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SARS-CoV-2 convalescent plasma | Protein / enzyme biologic | 180 ml | — |
| Subject | SARS-CoV-2 convalescent plasma | Protein / enzyme biologic | 200 ml | — |